Nutriband Inc. (NASDAQ: NTRB) Triggers 17 Bullish Signals On Way To New Makes New February High

*Sponsored by Nutriband Inc. Krypton Street Puts Nutriband Inc. (NASDAQ: NTRB) As Its Next Potential Breakout Idea For Friday, 2/7/2025. Nutriband Inc. (NASDAQ: NTRB) Moved Approximately 126% In Under 48 Hours Last Time We Covered It… Nutriband Inc. (NASDAQ: NTRB) Comes Backed By Several  Potential Catalysts Including: High-Conviction Analyst Coverage: Noble Capital’s Robert LeBoyer recently initiated coverage on NTRB with a bullish rating and a $13 target—suggesting over 103% in upside potential from recent range. Low Float: With fewer than 5.1M shares in the float, Nutriband Inc. (NASDAQ: NTRB) could witness the potential for significant swings if demand begins to shift. Recent Market Recognition: Nutriband Inc. (NASDAQ: NTRB) recently moved approximately 202% inside one week in January, displaying its swing potential. Technical Indicators: Currently trending above several key moving averages, which could suggest the potential for continued momentum.  Keep reading to see why Nutriband Inc. (NASDAQ: NTRB) is topping our watchlist this morning… February 7, 2025 Dear Reader, Did you pull up Nutriband Inc. (NASDAQ: NTRB) yet? Just minutes after the bell rang, (NTRB) triggered 17 Bullish Signals on TradingView’s technical analysis tool using the 15 minute time-frame, on its way to making a new February high of $8.63.  This marks an approximate 29% move from yesterday’s $6.67 close. Ahead of the open, Nutriband Inc. (NASDAQ: NTRB) received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its groundbreaking Aversa™ abuse-deterrent transdermal technology.  This expected patent issuance strengthens Nutriband Inc. (NASDAQ: NTRB)’s intellectual property protection and further solidifies its position in the abuse-deterrent pharmaceutical space. Why does this matter?  Aversa™ Fent-a-nyl could become the first and only abuse-deterrent pain patch on the market, a game-changing advancement in combating the opioid crisis.  With transdermal fent-a-nyl patches being widely used for pain management, Aversa™ is designed to prevent abuse, diversion, misuse, and accidental exposure, making it a critical innovation in the healthcare industry. With patents already granted in 46 countries, including the U.S., Europe, China, and Japan, Nutriband Inc. (NASDAQ: NTRB) is positioning itself as a global leader in transdermal abuse-deterrent technology.  The potential?  Peak annual U.S. sales of $80M to $200M if Aversa™ Fent-a-nyl reaches commercialization. With momentum building and this patent expected to be officially issued soon, Nutriband Inc. (NASDAQ: NTRB) is one to watch closely today. Keep reading to see why Nutriband Inc. (NASDAQ: NTRB) is topping our watchlist today. Let’s not beat around the bush. You see, the last time we covered Nutriband Inc. (NASDAQ: NTRB), it moved approximately 126% in under 48 hours.  Let’s face it—there aren’t many companies in the pharmaceutical innovation space quite like Nutriband Inc. (NASDAQ: NTRB).  While others stick to tired formulas and incremental changes, Nutriband Inc. (NASDAQ: NTRB) is establishing itself as a leader in the development of advanced transdermal technologies, addressing some of the most critical challenges in healthcare today. With a low float, of less than 5.1M shares listed, we’re keeping a close eye on Nutriband Inc. (NASDAQ: NTRB) because this scarcity could lead to the potential for significant swings if demand begins to change. In fact, Nutriband Inc. (NASDAQ: NTRB) recently moved approximately 202% in one week, from $3.90 on January 16th to $11.78 on January 23, 2025. Recently trending above several key moving averages, Nutriband Inc. (NASDAQ: NTRB) is showing strong technical momentum.  With its 20-day moving average at $6.44, 50-day at $5.21, 100-day at $5.57, and 200-day at $5.42, (NTRB) is currently trending above all long-term indicators tracked by Barchart—a bullish signal that could suggest further upside potential.  Additionally, its year-to-date moving average of $6.15 reinforces the notion that (NTRB) has been maintaining strength despite broader market fluctuations. Backing this momentum, insider ownership stands at over 54% as of yesterday—an exceptionally strong vote of confidence from those who know the company best. With more than half of all shares held by insiders, leadership is signaling long-term commitment and belief in future growth. This combination of technical strength and a market cap under $75M, could position (NTRB) as a high-growth candidate compared to larger players in the same space. Just over two weeks ago, Noble Capital’s Robert LeBoyer initiated coverage on (NTRB) with a Bullish Rating and a $13 target, which suggests over 103% upside potential from today’s $6.39 level. At the heart of this optimism is Nutriband Inc. (NASDAQ: NTRB)’s Phase 1 clinical trial, which is expected to showcase the effectiveness of its abuse-deterrent technology, setting up for an NDA filing by late 2025 and potential FDA approval in 2026. With a clear roadmap ahead and momentum at its back, Nutriband Inc. (NASDAQ: NTRB) is earning attention for all the right reasons. In a year where many companies struggled to stay relevant, (NTRB) refused to slow down—doubling down on its strategy, solidifying its position, and delivering results that speak for themselves. Trailblazing with AVERSA™ Fent-a-nyl Nutriband Inc. (NASDAQ: NTRB)’s crown jewel, AVERSA™ Fent-a-nyl, has redefined what’s possible in abuse-deterrent therapeutics.  This groundbreaking transdermal patch is designed not just to combat misuse but to revolutionize patient safety across the board.  With support from Kindeva Dr-ug Delivery, Nutriband Inc. (NASDAQ: NTRB) made significant headway in 2024: Completed pivotal validation studies, advancing the product closer to market readiness. Established a clear regulatory path for its New Application (NDA) submission in 2025, relying on a streamlined single Phase 1 Human Abuse Potential study. This isn’t just a pipe dream, either. If approved, AVERSA™ Fent-a-nyl is projected to rake in U.S. sales of $80M to $200M annually—a staggering testament to its market potential. Global Intellectual Property Domination Nutriband Inc. (NASDAQ: NTRB) isn’t just thinking local; they’re playing on a global stage. With patent approvals in China and Hong Kong, the company now boasts intellectual property coverage in 46 countries.  A U.S. Notice of Allowance for the AVERSA™ trademark further solidified their footing, giving competitors a clear signal: Nutriband Inc. (NASDAQ: NTRB) is here to lead. Strategic Fiscal Growth Numbers don’t lie.  Nutriband Inc. (NASDAQ: NTRB) reported record-breaking revenues in 2024, with their contract manufacturing arm, Pocono Pharma, leading the charge: A Q3 revenue of over $645k, representing a 51% year-over-year increase. Strengthened financial reserves, courtesy of $8.4M in fresh capital from a private placement. This fiscal foundation gives Nutriband Inc. (NASDAQ: NTRB) the firepower it needs to push AVERSA™ Fent-a-nyl over the finish line while continuing to innovate. Nutriband Inc. (NASDAQ: NTRB)’s 2025 Vision: Regulatory Milestones and Global Expansion Regulatory Milestones Await: The centerpiece of Nutriband Inc. (NASDAQ: NTRB)’s 2025 ambitions is the NDA submission for AVERSA™ Fent-a-nyl. With pivotal data in hand and no need for extended Phase 2 or Phase 3 trials, the company anticipates an expedited review process.  Translation? AVERSA™ Fent-a-nyl could be on the market before the year is out. Scaling for Success: Preparation for commercialization is already underway. Nutriband Inc. (NASDAQ: NTRB) is scaling its partnership with Kindeva Dr-ug Delivery to ensure manufacturing excellence.  Simultaneously, the company is laying the groundwork for international licensing and distribution agreements, proving that they aren’t content with U.S. dominance—they’re going global. A Pipeline with Potential: AVERSA™ Fent-a-nyl is just the beginning. Nutriband Inc. (NASDAQ: NTRB) is also advancing AVERSA™ Buprenorphine and exploring additional transdermal applications. If these developments live up to their promise, Nutriband Inc. (NASDAQ: NTRB) could unlock an entirely new revenue stream, with AVERSA™ Buprenorphine alone estimated to generate $130M annually. Beyond AVERSA™: Diversification and Innovation Nutriband Inc. (NASDAQ: NTRB) isn’t putting all its eggs in one basket. The company’s manufacturing arms—Pocono Pharma and Active Intelligence—are firing on all cylinders: Expanded partnerships with retail giants like Target, Walmart, Walgreens, and CVS. Delivered innovative kinesiology and consumer health products, including an exclusive supplier agreement with Fit For Life Group, which represents Adidas, Reebok, and New Balance. Launched a Mosquito Repellent Patch in Costa Rica, marking their entry into the lucrative Central and South American markets. Why It Matters Let’s not mince words: the opi-oid crisis remains one of the most devastating public health challenges of our time.  Nutriband Inc. (NASDAQ: NTRB) isn’t just talking about solutions; they’re delivering them.  The AVERSA™ technology represents a paradigm shift in patient safety, offering a tangible way to reduce misuse, accidental exposure, and diversion of high-risk therapeutics. As CEO Gareth Sheridan aptly put it, Nutriband Inc. (NASDAQ: NTRB) is “on the brink of a transformative period in its history.”  And he’s not wrong.  The company has not only set the stage for regulatory and commercial success but also laid a solid foundation for long-term growth. The Bottom Line Nutriband Inc. (NASDAQ: NTRB) isn’t just playing in the big leagues—it’s rewriting the rulebook. With AVERSA™ Fent-a-nyl on the cusp of commercialization, an ever-expanding pipeline, and strong fiscal performance, the company is positioning itself to drive innovation and make a real-world impact in healthcare. For those watching from the sidelines, here’s your wake-up call.  Nutriband Inc. (NASDAQ: NTRB) is not just about innovation; it’s about making a meaningful impact. See Nutriband Inc. (NASDAQ: NTRB)’s corporate presentation here. 7 Reasons Why Nutriband Inc. (NASDAQ: NTRB) is #1 On Our Pre-Market Watchlist… 1. Low Float: Nutriband Inc. (NASDAQ: NTRB)’s low float of under 5.1M shares could set the stage for significant swing potential if demand begins to change. 2. Market Recognition: Nutriband Inc. (NASDAQ: NTRB) moved approximately 202% inside a week in January, displaying its potential for significant swings. 3. Technical Indicators: Nutriband Inc. (NASDAQ: NTRB) is currently trending above several key moving averages, which could suggest the additional momentum potential. 4. Higher Growth Potential: Nutriband Inc. (NASDAQ: NTRB) currently has a market cap under $75M, offering the potential for higher growth compared to large-cap companies due to its smaller revenue base and operational flexibility. 5. Significant Insider Ownership: As of 2/6/2025, over 54% of shares are held by insiders, suggesting long-term commitment from those closest to the company. 6. Innovating with AVERSA™ Fent-a-nyl: Nutriband Inc. (NASDAQ: NTRB)’s flagship product is setting new standards in abuse-deterrent technology with regulatory milestones approaching. 7. Global Intellectual Property Strength: With patents in 46 countries and recent U.S. trademark approvals, Nutriband Inc. (NASDAQ: NTRB) is positioned for international impact. Consider Adding Nutriband Inc. (NASDAQ: NTRB) to Your  Radar This Morning… Let’s be real—there aren’t many companies out there making bold moves in biotech quite like Nutriband Inc. (NASDAQ: NTRB).  While some firms are busy rehashing the same old formulas, Nutriband Inc. (NASDAQ: NTRB) is out here rewriting the rulebook with AVERSA™ technology, a pipeline of game-changing products, and global patent protection to back it all up. With a low float, strong insider backing, and technicals lining up, (NTRB) isn’t just a name on a watchlist—it’s a company demanding attention.  And let’s not forget that (NTRB) recently showcased its swing potential with an approximate 202% move in just one week last month. Will history repeat itself?  Time will tell.  But one thing is for sure—we’re watching. We have all eyes on (NTRB) this morning.  Nutriband Inc. (NASDAQ: NTRB) triggered 17 Bullish Signals on TradingView’s technical analysis tool, on its way to making a new February high of $8.63, marking an approximate 29% move from yesterday’s close.  Please tell me you pulled this up. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 02/06/2025 and ending on 02/07/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, Media 1717 LLC has been paid an seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid fifteen thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (NTRB:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/ntrb/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice